{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:57:57Z","timestamp":1787018277817,"version":"build-2736575974"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Rifapentine has potent activity in mouse models of tuberculosis chemotherapy but its optimal dose and exposure in humans are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We conducted a randomized, partially blinded dose-ranging study to determine tolerability, safety, and antimicrobial activity of daily rifapentine for pulmonary tuberculosis treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with sputum smear-positive pulmonary tuberculosis were assigned rifapentine 10, 15, or 20 mg\/kg or rifampin 10 mg\/kg daily for 8 weeks (intensive phase), with isoniazid, pyrazinamide, and ethambutol. The primary tolerability end point was treatment discontinuation. The primary efficacy end point was negative sputum cultures at completion of intensive phase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>A total of 334 participants were enrolled. At completion of intensive phase, cultures on solid media were negative in 81.3% of participants in the rifampin group versus 92.5% (P\u2009=\u20090.097), 89.4% (P\u2009=\u20090.29), and 94.7% (P\u2009=\u20090.049) in the rifapentine 10, 15, and 20 mg\/kg groups. Liquid cultures were negative in 56.3% (rifampin group) versus 74.6% (P\u2009=\u20090.042), 69.7% (P\u2009=\u20090.16), and 82.5% (P\u2009=\u20090.004), respectively. Compared with the rifampin group, the proportion negative at the end of intensive phase was higher among rifapentine recipients who had high rifapentine areas under the concentration\u2013time curve. Percentages of participants discontinuing assigned treatment for reasons other than microbiologic ineligibility were similar across groups (rifampin, 8.2%; rifapentine 10, 15, or 20 mg\/kg, 3.4, 2.5, and 7.4%, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Daily rifapentine was well-tolerated and safe. High rifapentine exposures were associated with high levels of sputum sterilization at completion of intensive phase. Further studies are warranted to determine if regimens that deliver high rifapentine exposures can shorten treatment duration to less than 6 months.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT 00694629).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201410-1843oc","type":"journal-article","created":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T16:33:30Z","timestamp":1418142810000},"page":"333-343","source":"Crossref","is-referenced-by-count":98,"title":["Daily Rifapentine for Treatment of Pulmonary Tuberculosis. A Randomized, Dose-Ranging Trial"],"prefix":"10.1093","volume":"191","author":[{"given":"Susan E.","family":"Dorman","sequence":"first","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radojka M.","family":"Savic","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E.","family":"Stout","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Schluger","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Muzanyi","sequence":"additional","affiliation":[{"name":"Uganda\u2013Case Western Reserve University Research Collaboration, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Uganda\u2013Case Western Reserve University Research Collaboration, Kampala, Uganda"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Nahid","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J.","family":"Hecker","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Heilig","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Bozeman","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Jean I.","family":"Feng","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth N.","family":"Moro","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"},{"name":"CDC Foundation Research Collaboration, Atlanta, Georgia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"MacKenzie","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Dooley","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Nuermberger","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Vernon","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Weiner","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center at San Antonio and the South Texas VAMC, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,2,1]]},"reference":[{"key":"2026032100241545600_bib1","doi-asserted-by":"crossref","first-page":"13980","DOI":"10.1073\/pnas.0901720106","article-title":"Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics","volume":"106","author":"Abu-Raddad","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026032100241545600_bib2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0272-5231(21)00072-1","article-title":"Bacteriologic basis of short-course chemotherapy for tuberculosis","volume":"1","author":"Grosset","year":"1980","journal-title":"Clin Chest Med"},{"key":"2026032100241545600_bib3","first-page":"796","article-title":"Role of individual drugs in the chemotherapy of tuberculosis","volume":"4","author":"Mitchison","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026032100241545600_bib4","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100241545600_bib5","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1164\/ajrccm\/148.6_Pt_1.1541","article-title":"Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice","volume":"148","author":"Ji","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"2026032100241545600_bib6","first-page":"879","article-title":"U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis","volume":"119","author":"Long","year":"1979","journal-title":"Am Rev Respir Dis"},{"key":"2026032100241545600_bib7","first-page":"939","article-title":"The early bactericidal activity of drugs in patients with pulmonary tuberculosis","volume":"121","author":"Jindani","year":"1980","journal-title":"Am Rev Respir Dis"},{"key":"2026032100241545600_bib8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1164\/rccm.200411-1557OC","article-title":"The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis","volume":"172","author":"Sirgel","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100241545600_bib9","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1128\/AAC.01474-06","article-title":"Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears","volume":"51","author":"Diacon","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100241545600_bib10","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1093\/cid\/cir184","article-title":"Why do we use 600 mg of rifampicin in tuberculosis treatment?","volume":"52","author":"van Ingen","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2026032100241545600_bib11","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1164\/ajrccm\/141.3.626","article-title":"Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis","volume":"141","author":"Heifets","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"2026032100241545600_bib12","first-page":"437","article-title":"Single and multiple dose pharmacokinetics of rifapentine in man: part II","volume":"3","author":"Keung","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026032100241545600_bib13","first-page":"862","article-title":"Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis","volume":"8","author":"Langdon","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026032100241545600_bib14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/jac\/46.4.571","article-title":"Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex","volume":"46","author":"Bemer-Melchior","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2026032100241545600_bib15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials","volume":"40","author":"Burman","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"2026032100241545600_bib16","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1371\/journal.pmed.0040344","article-title":"Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model","volume":"4","author":"Rosenthal","year":"2007","journal-title":"PLoS Med"},{"key":"2026032100241545600_bib17","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1164\/rccm.200807-1029OC","article-title":"Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?","volume":"178","author":"Rosenthal","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100241545600_bib18","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1128\/AAC.00912-12","article-title":"Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis","volume":"56","author":"Rosenthal","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100241545600_bib19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/clpt.2011.323","article-title":"Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers","volume":"91","author":"Dooley","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2026032100241545600_bib20","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/infdis\/jis461","article-title":"Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium","volume":"206","author":"Dorman","year":"2012","journal-title":"J Infect Dis"},{"key":"2026032100241545600_bib21","author":"Dorman","year":"2013"},{"key":"2026032100241545600_bib22","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1080\/03610928308828586","article-title":"Some restricted randomization rules in sequential designs","volume":"12","author":"Soares","year":"1983","journal-title":"Commun Stat Theory Methods"},{"key":"2026032100241545600_bib23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: treatment of tuberculosis","volume":"167","author":"Blumberg","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100241545600_bib24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1378\/chest.115.1.12","article-title":"Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids","volume":"115","author":"Peloquin","year":"1999","journal-title":"Chest"},{"key":"2026032100241545600_bib25","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1128\/AAC.00345-10","article-title":"Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers","volume":"54","author":"Zvada","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100241545600_bib26","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1164\/rccm.200311-1612OC","article-title":"Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy","volume":"169","author":"Weiner","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100241545600_bib27","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1128\/AAC.01918-13","article-title":"Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability","volume":"58","author":"Savic","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100241545600_bib28","author":"Savic","year":"2013"},{"key":"2026032100241545600_bib29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1164\/rccm.200603-360OC","article-title":"Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis","volume":"174","author":"Burman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100241545600_bib30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1164\/rccm.200901-0078OC","article-title":"Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis","volume":"180","author":"Dorman","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100241545600_bib31","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"2026032100241545600_bib32","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"2026032100241545600_bib33","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/(SICI)1097-0258(19960715)15:13<1387::AID-SIM268>3.0.CO;2-R","article-title":"A non-parametric test for interval-censored failure time data with application to AIDS studies","volume":"15","author":"Sun","year":"1996","journal-title":"Stat Med"},{"key":"2026032100241545600_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i02","article-title":"Exact and asymptotic weighted logrank tests for interval censored data: the interval R package","volume":"36","author":"Fay","year":"2010","journal-title":"J Stat Softw"},{"key":"2026032100241545600_bib35","first-page":"1079","article-title":"Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis","volume":"1","author":"East African\/British Medical Research Council","year":"1972","journal-title":"Lancet"},{"key":"2026032100241545600_bib36","first-page":"1100","article-title":"Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis","volume":"2","author":"East African\/British Medical Research Council","year":"1974","journal-title":"Lancet"},{"key":"2026032100241545600_bib37","first-page":"39","article-title":"Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report: Third East African\/British Medical Research Councils study","volume":"118","author":"East African\/British Medical Research Council","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"2026032100241545600_bib38","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0041-3879(79)90001-1","article-title":"Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months","volume":"60","author":"Hong Kong Chest Service\/British Medical Research Council","year":"1979","journal-title":"Tubercle"},{"key":"2026032100241545600_bib39","first-page":"171","article-title":"Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis","volume":"1","author":"Hong Kong Chest Service\/British Medical Research Council","year":"1981","journal-title":"Lancet"},{"key":"2026032100241545600_bib40","first-page":"460","article-title":"A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy","volume":"126","author":"British Thoracic Association","year":"1982","journal-title":"Am Rev Respir Dis"},{"key":"2026032100241545600_bib41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/0003-4819-76-3-112-6-397","article-title":"USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results","volume":"112","author":"Combs","year":"1990","journal-title":"Ann Intern Med"},{"key":"2026032100241545600_bib42","author":"Boeree","year":"2013"},{"key":"2026032100241545600_bib43","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N Engl J Med"},{"key":"2026032100241545600_bib44","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","article-title":"A four-month gatifloxacin-containing regimen for treating tuberculosis","volume":"371","author":"Merle","year":"2014","journal-title":"N Engl J Med"},{"key":"2026032100241545600_bib45","first-page":"128","article-title":"A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"12","author":"Rustomjee","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026032100241545600_bib46","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(09)60333-0","article-title":"Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial","volume":"373","author":"Conde","year":"2009","journal-title":"Lancet"},{"key":"2026032100241545600_bib47","author":"Dooley","year":"2014"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/191\/3\/333\/67217506\/ajrccm_191_3_333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/191\/3\/333\/67217506\/ajrccm_191_3_333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:24:26Z","timestamp":1774067066000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/191\/3\/333\/8505163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,1]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,2,1]]},"published-print":{"date-parts":[[2015,2,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201410-1843oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,2]]},"published":{"date-parts":[[2015,2,1]]}}}